ClinicalTrials.gg
RecruitingNCT07748208Updated Nov 13, 2026

A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes

A Phase 2 interventional study of Inavolisib and Fulvestrant in Breast Cancer and Diabetes Type II, sponsored by Hoffmann-La Roche. Recruiting at 13 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Updated Nov 13, 2026Now RecruitingFirst sites in Puerto Rico and United States+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing inavolisib in Breast Neoplasms — 12 open to participants now, 15 under way, 4 of them phase 3. inavolisib · Breast Neoplasms.

Planned enrollment
16th of 16
40 · median 185
Started
2026
with 3 others
Phase 2
10 of 16
8 open now
Primary completion
2029-06
later than 11 of 14 live
Registered
16th of 16
by date
Lead sponsor
9 of 16
Hoffmann-La Roche

Among the 16 studies testing inavolisib in Breast Neoplasms, this one is the 16th largest by planned enrollment, is one of 4 that started in 2026, is one of 10 in phase 2, reaches primary completion later than 11 of the 14 other live ones, and was the 16th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

12 of the 16 studies testing inavolisib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About inavolisib

inavolisib: first FDA approval 2024 (ITOVEBI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing inavolisib in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the safety of inavolisib in combination with fulvestrant, with or without palbociclib, in participants with PIK3CA-mutated, HR+, HER2-negative ABC and type 2 diabetes.

03

Conditions studied

  • Breast Cancer
  • Diabetes Type II
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes with laboratory fasting blood glucose \< 185 milligrams per deciliter (mg/dL) and \<= 8% on any stable anti-hyperglycemic regimen excluding insulin short-term insulin dosing
  • Eligible for triplet of inavolisib, fulvestrant and palbociclib: no prior systemic therapy for locally advanced unresectable or disease
  • Confirmed diagnosis of HR+/- breast cancer
  • Confirmation of biomarker eligibility (detection of specified mutation(s) of PIK3CA via specified test)
  • per , Version 1.1 (RECIST v1.1)
  • (ECOG) Performance Status of 0-1
  • Adequate hematologic and organ function within 14 days prior to initiation of study treatment

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding, or intention of becoming pregnant during the study or within the time frame in which is required
  • Metaplastic breast cancer
  • Any history of Type 1 diabetes
  • Severe hyper- or hypoglycemia event within 6 months of initiation of study treatment
  • Any history of or carcinomatous meningitis
  • Known and untreated, or active central nervous system (CNS) Participants with a history of treated are eligible
  • Active inflammatory or conditions in either eye or history of idiopathic or -associated uveitis in either eye
  • Symptomatic active lung disease
  • History of active bowel inflammation or active inflammatory bowel disease
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Inavolisib + Fulvestrant + Palbociclib

    Participants will receive inavolisib and fulvestrant (and some participants palbociclib) as outlined in the intervention section.

    Drug: Inavolisib · Drug: Fulvestrant · Drug: Palbociclib

Interventions

  • Participants will receive oral inavolisib on Days 2-28 of each 28-day cycle.

    Also known as: RO7113755

  • Participants will receive intramuscular (IM) fulvestrant on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28-day cycle.

  • Some participants will receive oral palbociclib on Days 1-21 of each 28-day cycle.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Grade 4 Hyperglycemia Adverse Events (AEs) After Cycle 1

    Time frame: Up to approximately 21 months

  2. Percentage of Participants Hospitalized for Hyperglycemia or its Complications After Cycle 1

    Time frame: Up to approximately 21 months

  3. Percentage of Participants with AEs After Cycle 1

    Time frame: Up to approximately 21 months

Secondary outcomes

  1. Percentage of Particiants With Inavolisib-related Hyperglycemia AEs After Cycle 1

    Time frame: Up to Cycle 1 (each cycle is 28 days)

  2. Percentage of Participants With Inavolisib Discontinuations due to Hyperglycemia and its Complications

    Time frame: Up to approximately 21 months

  3. Percentage of Participants With Inavolisib Dose Reduction due to Hyperglycemia

    Time frame: Up to approximately 21 months

  4. Percentage of Participants With Return of Hemoglobin A1c or Glycated Hemoglobin (HbA1c) to Within 10% of Baseline Within 90 Days After Inavolisib Discontinuation

    Time frame: Up to approximately 21 months

  5. Number of Participants Reporting Presence,Frequency,Severity,&/or Degree of Interference with Daily Function of Selected Symptomatic Treatment Toxicities Assessed by NCI Patient-Reported Outcomes Common Terminology Criteria for AEs (PRO-CTCAE)

    Time frame: Up to approximately 21 months

  6. Percentage of Participants Reporting Each Response Option at Each Time Point for the Treatment Side-Effect Bother Item (GP5) From the Functional Assessment of Cancer Therapy - General (FACT-G) Questionnaire

    Time frame: Up to approximately 21 months

  7. Change from Baseline in Symptomatic Treatment-Related Toxicities as Assessed Through use of the PRO-CTCAE

    Time frame: Baseline, Up to approximately 21 months

  8. Change from Baseline in Treatment Side-Effect Bother as Assessed Through use of the FACT-G General Population, Question 5 (GP5) Item

    Time frame: Baseline, Up to approximately 21 months

  9. Objective Response Rate (ORR)

    Time frame: Up to approximately 21 months

  10. Best Overall Response Rate (BOR)

    Time frame: Up to approximately 21 months

  11. Duration of Response (DOR)

    Time frame: Up to approximately 21 months

  12. Progression-Free Survival (PFS)

    Time frame: Up to approximately 21 months

  13. Overall Survival (OS)

    Time frame: Up to approximately 21 months

  14. Mean and Mean Change From Baseline in Physical Function Score as Assessed by European Organisation for Research and Treatment of Cancer Item Library 17 (EORTC-IL17)

    Time frame: Baseline, up to approximately 21 months

  15. Mean and Mean Change From Baseline in Role Function Score as Assessed by EORTC-IL17

    Time frame: Baseline, up to approximately 21 months

  16. Mean and Mean Change From Baseline in Health-Related Quality of Life (HRQoL) Score as Assessed by EORTC-IL17

    Time frame: Baseline, up to approximately 21 months

07

Study locations

13 of 13 sites recruiting
  • Community Cancer Institute (CCI)
    Clovis, California 93611, United States
    Recruiting
  • The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente
    Torrance, California 90502-2006, United States
    Recruiting
  • MedStar Washington Hosp Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
  • Grady Memorial Hospital
    Atlanta, Georgia 30303-3031, United States
    Recruiting
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308-2212, United States
    Recruiting
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
    Recruiting
  • Nebraska Cancer Specialists St Francis - Grand Island
    Grand Island, Nebraska 68803, United States
    Recruiting
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68114, United States
    Recruiting
  • NYU Langone Hospital Long Island Clinical Research
    Mineola, New York 11501-4089, United States
    Recruiting
  • NYU Langone?s Perlmutter Cancer Center - 160 E 34th St
    New York, New York 10016-4744, United States
    Recruiting
  • West Cancer Center & Research Institute
    Germantown, Tennessee 38138-1762, United States
    Recruiting
  • West Virginia University
    Morgantown, West Virginia 26505, United States
    Recruiting
  • Pan American Center for Oncology Trials, LLC
    Dorado, 00646-2202, Puerto Rico
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2029, 30 months later.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's planned 30 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Aug 5, 2026
StartEst.
Nov 30, 2026was Oct 2026
Primary completionEst.
Jun 15, 2029
CompletionEst.
Sep 30, 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 20, 2026
Sites
13 sites added — first sites in Puerto Rico and United States
Show 13 added (12 United States, 1 Puerto Rico)
  • MedStar Washington Hosp Center · Washington D.C., United States
  • Grady Memorial Hospital · Atlanta, United States
  • Emory University Hospital Midtown · Atlanta, United States
  • Emory University Hospital · Atlanta, United States
  • Nebraska Cancer Specialists St Francis - Grand Island · Grand Island, United States
  • Nebraska Cancer Specialists · Omaha, United States
  • NYU Langone Hospital Long Island Clinical Research · Mineola, United States
  • NYU Langone?s Perlmutter Cancer Center - 160 E 34th St · New York, United States
  • West Virginia University · Morgantown, United States
  • Pan American Center for Oncology Trials, LLC · Dorado, Puerto Rico
  • Community Cancer Institute (CCI) · Clovis, United States
  • The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente · Torrance, United States
  • West Cancer Center & Research Institute · Germantown, United States
across 2 updates, Oct 20, 2026 – Nov 13, 2026
Start date
Oct 30, 2026→Nov 30, 2026
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    3 sites added
    Show 3 added (3 United States)
    • Community Cancer Institute (CCI) · Clovis, United States
    • The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Cente · Torrance, United States
    • West Cancer Center & Research Institute · Germantown, United States
    Start date Oct 30, 2026→Nov 30, 2026
    + 1 other change: verification date
  2. Oct 20, 2026
    Not yet recruiting→Recruiting
    10 sites added — first sites in Puerto Rico and United States
    Show 10 added (9 United States, 1 Puerto Rico)
    • MedStar Washington Hosp Center · Washington D.C., United States
    • Grady Memorial Hospital · Atlanta, United States
    • Emory University Hospital Midtown · Atlanta, United States
    • Emory University Hospital · Atlanta, United States
    • Nebraska Cancer Specialists St Francis - Grand Island · Grand Island, United States
    • Nebraska Cancer Specialists · Omaha, United States
    • NYU Langone Hospital Long Island Clinical Research · Mineola, United States
    • NYU Langone?s Perlmutter Cancer Center - 160 E 34th St · New York, United States
    • West Virginia University · Morgantown, United States
    • Pan American Center for Oncology Trials, LLC · Dorado, Puerto Rico
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07748208
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 5, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Jun 15, 2029 (estimated)
Completion
Sep 30, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Reference Study ID Number: GO45322 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inavolisib

Start the discussion